Biotech Bankruptcies: BIND and NephroGenex Weigh Options
Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.
You may also be interested in...
US firm NephroGenex, which conducted its initial public offering early this year, saw its share price close up almost 300% at $13.35 on 31 December on news that its sole drug candidate, Pyridorin, was found to be safe in a cardiac safety study.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.